HDAC1-IN-13
HDAC1-IN-13 is an orally active HDAC1 inhibitor with IC50 values of 91, 185, 170, and 280 nM against HDAC1, HDAC2, HDAC3, and HDAC10, respectively, and shows no activity against HDAC4, HDAC5, HDAC6, HDAC7, and HDAC9. HDAC1-IN-13 induces extrinsic apoptosis by activating the caspase-8 pathway and triggers G0/G1 cell cycle arrest. HDAC1-IN-13 can be used for the research of leukemia.
For research use only. We do not sell to patients.
- CAS No.: 3053289-22-5
- Formula: C23H20N4O
- Molecular Weight:368.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
HDAC1 91 nM (IC50) |
HDAC2 181 nM (IC50) |
HDAC3 170 nM (IC50) |
HDAC10 280 nM (IC50) |
Caspase-8 |
In Vitro
HDAC1-IN-13 (Compound 6B) potently inhibits HDAC1 (IC50 = 91 nM), HDAC2 (IC50 = 185 nM), HDAC3 (IC50 = 170 nM), and HDAC10 (IC50 = 280 nM) enzymes, with no activity against HDAC4, HDAC5, HDAC7, HDAC8, or HDAC9[1].
HDAC1-IN-13 (Compound 6B) (72 h) potently inhibits the proliferation of HL-60 (IC50 = 0.31 μM), CCRF-CEM (IC50 = 0.36 μM), and HepG2 (IC50 = 1.01 μM) cancer cells in vitro[1].
HDAC1-IN-13 (Compound 6B) (72 h) has low cytotoxicity to LO2 normal human hepatocytes (IC50 = 5.67 μM) and a high selectivity index of 18.3 relative to HL-60 cancer cells[1].
HDAC1-IN-13 (Compound 6B) (0.1-2.5 μM; 48 h) concentration-dependently increases histone H3 acetylation, downregulates Rb/p-Rb and caspase-8 precursor, and modulates BAX, BAK, and BCL-2 expression in HL-60 cells after 48 h of treatment[1].
HDAC1-IN-13 (Compound 6B) (0-2.5 μM; 48 h) concentration-dependently induces apoptosis in HL-60 cells, with a 46.1% apoptosis rate following 48 h treatment with 2.5 μM[1].
HDAC1-IN-13 (Compound 6B) (0-2.5 μM; 48 h) concentration-dependently induces G0/G1 phase cell cycle arrest in HL-60 cells, with 76.5% of cells arrested in G0/G1 following 48 h treatment with 2.5 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HL-60 promyelocytic leukemia cells
-
Concentration:0.1 μM, 0.5 μM, 2.5 μM
-
Incubation Time:48 h
-
Result:Induced a concentration-dependent increase in acetylated histone H3 (Ac-H3) levels, while total histone H3 levels remained unchanged.
Downregulated expression of Rb, phosphorylated Rb (p-Rb), and caspase-8 precursor in a concentration-dependent manner.
Downregulated BAX, BAK, and BCL-2 expression.
-
Cell Line:HL-60 promyelocytic leukemia cells
-
Concentration:0 μM, 0.1 μM, 0.5 μM, 2.5 μM
-
Incubation Time:48 h
-
Result:Induced apoptosis in a concentration-dependent manner, with apoptosis rates of 13.87% (0 μM), 25.6% (0.1 μM), 27.6% (0.5 μM), and 46.1% (2.5 μM).
Reached a late apoptotic cell proportion of 22.7% at the highest concentration.
-
Cell Line:HL-60 promyelocytic leukemia cells
-
Concentration:0 μM, 0.1 μM, 0.5 μM, 2.5 μM
-
Incubation Time:48 h
-
Result:Induced G0/G1 phase cell cycle arrest in a concentration-dependent manner, with the proportion of cells in G0/G1 phase increasing from 56.4% (0 μM) to 76.5% (2.5 μM).
Parmacokinetics
In Vivo
HDAC1-IN-13 (20 mg/kg; i.p.; once daily; for 7 consecutive days) exhibits potent in vivo anti-leukemia activity with no obvious toxicity in mouse models following intraperitoneal administration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (male, 6-8 weeks old, 18-22 g, subcutaneous xenograft model)[1]
-
Dosage:15 mg/kg; 30 mg/kg
-
Administration:i.g.; daily; 18 days
-
Result:Achieved a tumor growth inhibition (TGI) rate of 20.72% at 30 mg/kg.
Showed no obvious pathological changes in heart, liver, spleen, lung, or kidney tissue.
Maintained stable mouse body weights throughout the study.
-
Animal Model:BALB/c nude (male, 6-8 weeks old, 18-22 g, subcutaneous xenograft model)[1]
-
Dosage:20 mg/kg
-
Administration:i.p.; daily; 7 days
-
Result:Reduced tumor volume by 58.4% after 7 days.
Showed no changes in mouse body weight during the study, indicating low in vivo toxicity.
Chemical Information
-
CAS No. 3053289-22-5
-
Molecular Weight 368.43
-
Formula C23H20N4O
-
SMILES
O=C(NC1=CC=CC=C1N)C(C=C2)=CC=C2CNC3=CC=NC4=CC=CC=C43
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)